読み込み中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新データ
$42.67
+$0.53 · +1.26%
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
前日終値
$42.67
+$0.53 · +1.26%
日中の時刻はETです。市場データは遅延する場合があります。
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
日中レンジ
現在 $42.67
52週レンジ
現在 $42.67
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
26
割高
センチメント
48
まちまち
リスク
31
中程度のリスク
モメンタム
59
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
日中レンジ
現在 $42.67
52週レンジ
現在 $42.67
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 7.19億 USD | 6.62億 USD | 6.08億 USD | 6.67億 USD | 5.8億 USD |
| 売上原価 | 7456.2万 USD | 7790.6万 USD | 8377.9万 USD | 8722.1万 USD | 7506.1万 USD |
| 粗利益 | 6.44億 USD | 5.84億 USD | 5.24億 USD | 5.8億 USD | 5.05億 USD |
| 研究開発 | 1.06億 USD | 1.09億 USD | 9159.3万 USD | 7455.2万 USD | 9046.7万 USD |
| 販売・一般管理 | 4.86億 USD | 3.36億 USD | 3.36億 USD | 3.77億 USD | 3.05億 USD |
| 営業費用 | 6.81億 USD | 5.02億 USD | 5.29億 USD | 5.34億 USD | 4.19億 USD |
| 受取利息 | 1325.3万 USD | 1620.4万 USD | 1045.3万 USD | 2168.9万 USD | 1056.9万 USD |
| 支払利息 | — | — | 241.5万 USD | 707万 USD | 2342.3万 USD |
| 減価償却費と償却費 | 9156.3万 USD | 8041.4万 USD | 8485.9万 USD | 8554.3万 USD | 3259.5万 USD |
| 営業利益 | −3686.4万 USD | 8166.6万 USD | −526.9万 USD | 4612.4万 USD | 8602.9万 USD |
| 純利益 | −3855万 USD | 7386.5万 USD | 131.6万 USD | 6071.1万 USD | 5342.4万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$57.60
上昇余地（34.99%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI7764.47万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM6193.76万0.08%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB5600.45万0.03%1853億 USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR3561.94万0.05%682億 USD0.05%$234.43+0.22%
Vanguard Extended Market ETFVXF2975.78万0.03%954億 USD0.05%$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM2255.01万0.14%158.4億 USD0.03%$53.45+0.17%
Dimensional - US Small Cap ETFDFAS1927.75万0.06%338.69億 USD0.31%$78.35+0.32%
Dimensional - US Targeted Value ETFDFAT1674.33万0.06%301.22億 USD0.33%$67.27-0.43%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMDimensional - US Small Cap ETFDFASDimensional - US Targeted Value ETFDFATAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
